Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ophthotech Corp    OPHT

OPHTHOTECH CORP (OPHT)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/17/2018 09/18/2018 09/19/2018 09/20/2018 09/21/2018 Date
2.35(c) 2.36(c) 2.41(c) 2.46(c) 2.33(c) Last
66 862 78 430 187 595 117 467 226 601 Volume
-1.67% +0.43% +2.12% +2.07% -5.28% Change
More quotes
Financials (USD)
Sales 2018 -
EBIT 2018 -61,0 M
Net income 2018 -59,0 M
Debt 2018 -
Yield 2018 -
Sales 2019 -
EBIT 2019 -66,0 M
Net income 2019 -62,0 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 0
Capi. / Sales2019 0
Capitalization 84,3 M
More Financials
Company
Ophthotech Corp. is a biopharmaceutical company,which engages in discovering, developing, and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases.Its product candidates include Zimura and Gene Therapy.The company was founded by... 
More about the company
Surperformance© ratings of Ophthotech Corp
Trading Rating : - Investor Rating :
More Ratings
Latest news on OPHTHOTECH CORP
08/23OPHTHOTECH CORPORATION : - Scientific Data for Novel Adeno-Associated Virus Gene..
AQ
08/22OPHTHOTECH CORP. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
08/22OPHTHOTECH : Scientific Data for Novel Adeno-Associated Virus Gene Therapy in Rh..
BU
08/09OPHTHOTECH : Reports Second Quarter 2018 Financial and Operating Results
AQ
08/07OPHTHOTECH : Reports Second Quarter 2018 Financial and Operating Results
AQ
08/01OPHTHOTECH : Management's Discussion and Analysis of Financial Condition and Res..
AQ
08/01OPHTHOTECH : 2Q Earnings Snapshot
AQ
08/01OPHTHOTECH CORP. : Results of Operations and Financial Condition (form 8-K)
AQ
08/01OPHTHOTECH : Reports Second Quarter 2018 Financial and Operating Results
BU
08/01ROBBINS ARROYO LLP : Ophthotech Corporation (OPHT) Misled Shareholders According..
BU
More news
Sector news : Bio Therapeutic Drugs
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug in First European Setback -..
DJ
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug for Some Patients Despite D..
DJ
09/19GILEAD SCIENCES : UK rejects adult Novartis CAR-T therapy, after 'yes' in kids
RE
09/18REGENERON PHARMACEUTICALS : Sanofi pledges to keep up its restructuring efforts
RE
09/14Allogene, Which Announced Pfizer Agreement in April, Discloses IPO Plans
DJ
More sector news : Bio Therapeutic Drugs
Latest Tweets
09/23Brokerages Expect Ophthotech Corp $OPHT Will Announce Earnings of -$0.43 Per ..
1
09/11Get the latest ratings for $KDP $FCB $CNXM $VTAE $OPHT in your inbox with Mar.. 
09/06Ophthotech Corp $OPHT Receives $4.00 Average Target Price from Brokerages  
09/05ValuEngine Downgrades Ophthotech $OPHT to Strong Sell  
08/26Contrasting Ophthotech $OPHT and Syndax Pharmaceuticals $SNDX  
More tweets
Qtime:21
News from SeekingAlpha
08/01Ophthotech files for $150M mixed shelf offering; share down 2% after hours 
08/01Ophthotech Corp (OPHT) CEO Glenn Sblendorio on Q2 2018 Results - Earnings Cal.. 
08/01Ophthotech beats by $0.02 
06/11YOUR DAILY PHARMA SCOOP : Aduro Biotech Moves Ahead, MannKind Up, Chimerix Dips 
06/07Midday Gainers / Losers (06/07/2018) 
Chart OPHTHOTECH CORP
Duration : Period :
Ophthotech Corp Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OPHTHOTECH CORP
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Average target price 3,25 $
Spread / Average Target 39%
EPS Revisions
Managers
NameTitle
Glenn P. Sblendorio President, Chief Executive Officer & Director
David R. Guyer Executive Chairman
Keith Westby Chief Operating Officer & Senior Vice President
David F. Carroll CFO, Treasurer, Principal Accounting Officer & SVP
Evelyn M. Harrison Chief Clinical Operations Officer
Sector and Competitors
1st jan.Capitalization (M$)
OPHTHOTECH CORP-25.32%89
GILEAD SCIENCES5.40%97 887
VERTEX PHARMACEUTICALS20.17%46 021
REGENERON PHARMACEUTICALS3.81%41 426
NEUROCRINE BIOSCIENCES, INC.54.17%10 822
GENMAB2.04%10 170